BTN3A1 and ovarian carcinoma: Trials have demonstrated that antibodies targeting CD277 can change BTN3A1 from an immune suppressor to an immune stimulator, thereby dynamically eliciting antitumor immunity driven by coordinated αβ T and γδ T cells, halting the progression of ovarian cancer [120].